MedTrace Logo

Skin Prick Tests With AllerT in Subjects Allergic to Birch Pollen

NCT01719133 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-11-01

No results posted yet for this study

Summary

Assessment of skin reactivity by skin prick tests to synthetic peptides derived from the major birch allergen bet v 1, in subjects allergic to birch pollen.

Conditions

  • Allergic Rhinitis

Interventions

DRUG

placebo

saline solution

DRUG

Histamine

positive control

DRUG

AllerT1

synthetic peptide T1

DRUG

AllerT2

synthetic peptide T2

DRUG

AllerT3

synthetic peptide T3

DRUG

AllerT4

synthetic peptide T4

DRUG

AllerT5

synthetic peptide T5

DRUG

mix of AllerT1-T2-T3

mix of peptides T1, T2 and T3

DRUG

mix of AllerT4-T5

mix T4-T5

Sponsors & Collaborators

  • Anergis

    lead INDUSTRY

Principal Investigators

  • Francois Spertini, MD · Centre Hospitalier Universitaire Vaudois

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-03-31
Completion
2008-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01719133 on ClinicalTrials.gov